Lilly will use Rznomics’ proprietary ribozyme technology to develop RNA editing therapies for congenital hearing loss.

The star of the acquisition is the enzyme replacement therapy INZ-701, being developed for the rare disease ENPP1 deficiency.

Over Lars Fruergaard Jørgensen's eight years as CEO, Novo’s sales, profits and share price have almost tripled, the company ...

Roche committed $50 billion in U.S. manufacturing funds, with which it will construct at least four new facilities.

The FDA also approved the use of Zynyz as a monotherapy for patients with squamous cell carcinoma of the anal canal who are ...

Since Elevidys' accelerated approval in 2023, experts have been clamoring for more data, particularly in older and ...

Sanofi expects to add “a significant number of high-paying jobs” in the U.S. with $20 billion investment through 2030.

AbbVie's Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who ...

As the FDA prepares for a busy Oncologic Drugs Advisory Committee meeting next week, an agency insider told BioSpace that ...

The FDA also changed its tune and is now planning to convene an advisory committee to discuss Biohaven’s application.

After warnings that the dragged-out process was putting the cell therapy company at risk of bankruptcy, bluebird bio now has ...

At a sometimes-contentious U.S. Senate hearing, the Health and Human Services secretary was evasive on the rationale behind ...